7. Patients with known history of cardiac arrhythmias including atrial fibrillation, tachyarrhythmias or bradycardia will be excluded. Patients receiving therapeutic agents known to prolong QT interval will be excluded. Patients with history of CHF, or MI or stroke in the last 3 months will be excluded. Patients with a history of seizures will be excluded form the initial trial because ONC201 crosses the blood-brain barrier and this may affect their anti-seizure therapy.